Latest Conference Articles

Experts Highlight Noteworthy Research From the 2024 ESMO Congress

Oncology experts share notable clinical trials and up-and-coming therapies presented at the 2024 ESMO Congress.

MR-Linac Radiotherapy Limits Target Volume, Brain Tissue Exposure in High-Grade Glioma

PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma

Patients with WHO grade II/III recurrent meningioma experienced clinically meaningful efficacy with 177Lutetium-Dotatate.

Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer

The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.

Atezolizumab Plus Chemoradiation Provides No Survival Benefit in LS-SCLC

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma

MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.

Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma

The second-generation, BCMA-directed CAR T-cell therapy HBI0101 led to an objective response rate of 92% in patients with relapsed/refractory multiple myeloma.

Dr Dhakal on Survival and Safety Outcomes With Cilta-Cel in R/R Myeloma

Binod Dhakal, MD, discusses survival data with ciltacabtagene autoleucel in lenalidomide-refractory relapsed/refractory multiple myeloma.

Dr Corre on MRD Negativity With D-VTd Induction/Consolidation in Newly Diagnosed Multiple Myeloma

Jill Corre, PharmD, PhD, discusses minimal residual disease negativity rates after treatment with D-VTd induction/consolidation in newly diagnosed multiple myeloma.

BPd Maintains QOL vs PVd, Supporting Its Use as a New SOC in R/R Myeloma

No significant differences in patient-reported outcomes were observed with BPd vs PVd among patients with relapsed/refractory multiple myeloma.

HDP-101 Shows Early Efficacy and Manageable Safety Profile in Relapsed/Refractory Multiple Myeloma

The BCMA-targeting ADC HDP-101 demonstrated early efficacy and manageable toxicity in relapsed/refractory multiple myeloma.

Trastuzumab/Pertuzumab May Be an Effective Chemo-Free Regimen in HR+/HER2+ Breast Cancer

Dual HER2 blockade with trastuzumab plus pertuzumab may serve as an effective option for hormone receptor–positive, HER2-positive metastatic breast cancer.

Cilta-Cel Shows Real-World Feasibility and Efficacy With Acceptable Safety in R/R Myeloma

Cilta-cel elicits high response rates with an acceptable toxicity profile in a real-world population of patients with relapsed/refractory multiple myeloma.

Dr Usmani on the Efficacy of Daratumumab Plus VRd in Newly Diagnosed, Transplant-Ineligible Myeloma

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the efficacy of daratumumab plus VRd in patients with transplant-ineligible or -deferred multiple myeloma.

Targeted Treatment Provides ORR and PFS Benefit in Pretreated Metastatic Solid Tumors

Targeted treatment as determined by mutational status was associated with ORR and PFS benefits in pretreated patients with metastatic solid tumors.

Dr Badros on the Efficacy of Daratumumab Plus Lenalidomide in Newly Diagnosed Myeloma

Ashraf Badros, MBCHB, discusses the addition of subcutaneous daratumumab to lenalidomide vs lenalidomide alone in newly diagnosed myeloma following ASCT.

Fecal Microbiota Transplantation Boosts Response to Pembrolizumab Plus Axitinib in mRCC

The addition of fecal microbiota transplantation to pembrolizumab and axitinib raised the efficacy of the combination in metastatic renal cell carcinoma.

BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma

The GPRC5D-targeted CAR T-cell therapy BMS-986393 led to an objective response rate of 96% in patients with relapsed/refractory multiple myeloma.

Daratumumab Plus RVd as Induction Therapy Improves Responses, Survival in Newly Diagnosed Myeloma

The data are part of the largest reported cohorts of consecutive and uniformly treated real-world patients with newly diagnosed multiple myeloma.

Mezigdomide Plus Tazemetostat and Dexamethasone Is Effective and Safe in Refractory Myeloma

Mezigdomide, tazemetostat, and dexamethasone demonstrated early efficacy signals in patients with refractory multiple myeloma.

Belantamab Mafodotin Plus KRd Is Effective With Manageable Toxicities in R/R Multiple Myeloma

Belantamab mafodotin plus KRd was associated with a manageable safety profile and deep responses in pretreated patients with multiple myeloma.

Anito-Cel Yields 100% Response Rate in R/R Myeloma

All patients with relapsed/refractory multiple myeloma experienced a response when treated with anitocabtagene autoleucel in a phase 1 trial.

Durcabtagene Autoleucel Yields High Response Rates in R/R Myeloma

Durcabtagene autoleucel generated responses with a tolerable safety profile in relapsed/refractory multiple myeloma.

Daratumumab Plus VRd Improves MRD Negativity in Newly Diagnosed, Transplant-Ineligible or -Deferred Myeloma

Daratumumab plus VRd improved MRD-negativity rates in transplant-ineligible or -deferred, newly diagnosed multiple myeloma.

Daratumumab/Lenalidomide Improves MRD– Conversion Rates in Newly Diagnosed Myeloma After ASCT

Daratumumab/lenalidomide maintenance increased MRD-negative conversion rates vs lenalidomide alone in newly diagnosed multiple myeloma after transplant.

Isa-KRd Induction Therapy Elicits Responses, MRD Negativity in Transplant-Eligible, Newly Diagnosed Myeloma

Patients with newly diagnosed, transplant-eligible multiple myeloma achieved deep responses and MRD negativity with isa-KRd induction therapy.

Talquetamab-Based Triplet Elicits Deep Responses in R/R Myeloma

Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.

Talquetamab Plus Teclistamab Demonstrates Durable Responses in Triple Class–Exposed R/R Myeloma

Combining talquetamab with teclistamab demonstrated responses even among those with extramedullary disease in the RedirecTT-1 trial.

Radium-223 Before Docetaxel Demonstrates Better QOL in mCRPC, With No Difference in Survival

D-VRd Extends PFS in Newly Diagnosed Multiple Myeloma Subgroups

D-VRd induction and consolidation therapy displayed a PFS benefit vs VRd in high-risk subgroups of patients with newly diagnosed multiple myeloma.